Loading presentation...

Present Remotely

Send the link below via email or IM

Copy

Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.

DeleteCancel

H&H V5R1

No description

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of H&H V5R1

30 years

of early-stage investing and company building experience
A subset of these investments helped
identify the potential

of this opportunity
5+ years

exclusively focused on the
life science space
We’re here to talk about
healthcare
, we’re going to lay out a vision, why we have the power to change, why it won’t happen, lay out how we can catalyze that change.
Connectivity is complete, with greater than 80% smart phone usage
Clinical is fragmented
Pharma
Pharma is willing to pay for data
Baby Boomers
Generation X
Millenials
Children
Technology
71%
want to use an app to manage their health records.
63%
would share wearable data with physician
(but doctors don’t want it).
Each hospital is covered with a different EMR and a different set of languages - No interoperability.
Primary Care
Pediatric
Neurology
United States of Healthcare
A Harris & Harris Group Company
_ __ _ _ _ _ _ _ _
Corporations
Consumers
Consumers
Pharma/R&D
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ _ _
_ _ _
Phenome
_ _ _ _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Primary Care
_ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ _ _ _
_ _ _
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
_
_ _ _ _ _ _ _ _ _ _ _ _ _ _
Pediactric
_ _ _ _ _ _ _ _ _
Consumer
_ _ _ _ _ _ _ _
Clinical Providers
Regulation
_ _ _ _ _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ _ _ _
Different gauge didn’t allow interoperability
Without access, resources went underutilized.
Fragmented population and service providers
In US alone, a
$3 Trillion
Industry with

300 million
consumers
that is ripe for disruption.

$
EMRs and Interoperability
Patients have access to information
Accountable Care Organizations
(Fixed Fee Medicine)
Current state of Health Care landscape:
· New Technologies
· Large datasets
· Limited connection to consumers
· Institutions changing by regulations
· Disparate systems
Systemized cars for easy transport
Transportation hubs developed, lead to further value-added services
Interoperable track
Safe Harbor Statement
This presentation may contain statements of a forward-looking nature relating to future events. Statements contained in this presentation that are forward-looking statements are intended to be made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company’s current beliefs, and a number of important factors could cause actual results to differ materially from those expressed herein.

Please see the Company’s Annual Report on Form 10-K, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company’s business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company’s actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc. undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

Genome
Orthopedic
Geriatric
Fertility
Identified an area currently experiencing

massive disruption

and a plan to

unlock value
How did we get here?
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Fertility Clinicians
Researchers
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Consumers
Pharma/R&D
Phenome
Genetics
Healthcare is facing fundamental challenges.
_ _ _ _ _ _ _ _ _ _ _
_ _
_ _ _
_ _
CONNECTED HEALTHCARE
_ _ _
_ _ _ _ _ _ _ _
We have proactively gathered many of the core assets to enable this new reality and have identified others to be added. Synergies across portfolio will enhance individual component value. Ready to take next step.
NOT

SUSTAINABLE
NOT
EFFECTIVE
NOT
EVIDENCE BASED
Precision medicine not adopted
, still 1st, 2nd, 3rd … line therapies
Over 1/3 of time

with patients spent at a computer
Oncology
Cardiology
Cost of healthcare is growing at

GDP + 2%
Over 80%

of expenditures are on chronic disease
($2 Trillion)
Complexity has skyrocketed:
7 providers for patients over 65
Build a truly connected health ecosystem that is customer, non clinician, focused and connects orthogonal data sets to deliver optimized health and wellness data, creating massive value in a $3 Trillion industry.
Pharmacogenetics

proven in over 100 drugs
, but not used
And it could take 60 years to adopt solutions…
Disparate and frustrated patient population
Fragmented clinical providers
Pharma starved for new information sources
Technologies don’t communicate
Payers desperately seeking efficiency
Promise of Precision Medicine
not being met
Better outcomes

not being seen
Costs
not being reduced
We have identified the fundamental challenges and opportunities in the industry, gathered the key pieces of the system, and are primed to launch a health-focused initiative to take advantage of this disruptive period with a value-enhancing methodology for investment.
How we see the landscape…
There is a fundamental shift in the application and approach to healthcare:
Changing demographics are disrupting patient base
What is missing:
Multi-omic data AND we don’t have an engine that can interrogate all of the data and provide actionable information
Dire need

for more physicians / increase efficiency of current workforce
(>45,000 physician shortfall in 2025)
System cannot adopt new

data sources
Connectivity is driving patient interaction
Big Data driving interpretation
Domestic policies are forcing institutional change
$1000 Genome paired with orthogonal ‘omics is providing quantifiable data
NOT

WORKING
NOT EVIDENCE BASED
NOT

SUSTAINABLE
Genetech signed a

$60 million

deal with
23&me
for access to a portion of their data.
Roche
buys majoritiy stake in
Foundation Medicine
for
$1 Billion
Roche
leads

$175 million
investment into
Flatiron Health
Companies
+24
Companies
+11
Phenome
Companies
+14
Physiome
Companies
+4
Companies
+3
Companies
+5
Companies
+3
Companies
+2
Anatome
Metabolome
Transcriptome
Epigenome
Proteome
Microbiome
Exposome
Full transcript